

# Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study

Vania Tietsche de Moraes Hungria, PhD, MD<sup>1</sup>; Carlos Chiattone, PhD, MD<sup>2</sup>; Miguel Pavlovsky, MD<sup>3</sup>; Lina M. Abenoza, MD<sup>4</sup>; Gladys P. Agreda, MD<sup>5</sup>; Jorge Armenta, MD<sup>6</sup>; Celso Arrais, MD, PhD<sup>7</sup>; Oscar Avendaño Flores, MD<sup>8</sup>; Fernando Barroso, PhD, MD<sup>9</sup>; Ana L. Basquiera, MD, PhD<sup>10</sup>; Carmen Cao, MD<sup>11</sup>; Maria S. Cugliari, MD<sup>12</sup>; Alicia Enrico, MD<sup>13</sup>; Laura M. Fogliatto, MD, PhD<sup>14</sup>; Kenny M. Galvez, MD<sup>15</sup>; David Gomez, MD<sup>16</sup>; Alvaro Gomez, MD<sup>17</sup>; Daniel de Iracema, MD<sup>18</sup>; Danielle Farias, MD<sup>19</sup>; Lineth Lopez, MD<sup>20</sup>; William Armando Mantilla, MD<sup>21</sup>; Deborah Martínez, PhD<sup>5</sup>; Maria Jose Mela, MD<sup>3</sup>; Carlos E. Miguel, MD<sup>22</sup>; Roberto Ovilla, MD<sup>23</sup>; Luis Palmer, MD<sup>24</sup>; Carolina Pavlovsky, MD<sup>3</sup>; Christian Ramos, MD<sup>25</sup>; Guillermina Remaggi, MD<sup>3</sup>; Rodrigo Santucci, MD<sup>26</sup>; Sergio Schusterschitz, MD<sup>27</sup>; Claudia Lucia Sossa, MD<sup>28</sup>; Elena Tuna-Aguilar, MD<sup>5</sup>; Jorge Vela, MD<sup>29</sup>; Telma Santos, MD<sup>30</sup>; Odin de la Mora, MD<sup>25</sup>; Gerardo Machnicki, PhD<sup>31</sup>; Mariana Fernandez, MD<sup>31</sup>; and Paula Barreyro, MD<sup>31</sup>

## abstract

**PURPOSE** Limited information is available on multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) management in Latin America. The primary objective of the Hemato-Oncology Latin America (HOLA) study was to describe patient characteristics and treatment patterns of Latin American patients with MM, CLL, and NHL.

**METHODS** This study was a multicenter, retrospective, medical chart review of patients with MM, CLL, and NHL in Latin America identified between January 1, 2006, and December 31, 2015. Included were adults with at least 1 year of follow-up (except in cases of death within 1 year of diagnosis) treated at 30 oncology hospitals (Argentina, 5; Brazil, 9; Chile, 1; Colombia, 5; Mexico, 6; Panama/Guatemala, 4).

**RESULTS** Of 5,140 patients, 2,967 (57.7%) had NHL, 1,518 (29.5%) MM, and 655 (12.7%) CLL. Median follow-up was 2.2 years for MM, 3.0 years for CLL, and 2.2 years for NHL, and approximately 26% died during the study observation period. Most patients had at least one comorbidity at diagnosis. The most frequent induction regimen was thalidomide-based chemotherapy for MM and chlorambucil with or without prednisone for CLL. Most patients with NHL had diffuse large B-cell lymphoma (DLBCL; 49.1%) or follicular lymphoma (FL; 19.5%). The majority of patients with DLBCL or FL received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

**CONCLUSION** The HOLA study generated an unprecedented level of high-quality, real-world evidence on characteristics and treatment patterns of patients with hematologic malignancies. Regional disparities in patient characteristics may reflect differences in ethnoracial identity and level of access to care. These data provide needed real-world evidence to understand the disease landscape in Latin America and may be used to inform clinical and health policy decision making.

J Global Oncol. © 2019 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License 

## ASSOCIATED CONTENT

## Appendix

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on June 11, 2019 and published at [ascopubs.org/journal/jgo](https://ascopubs.org/journal/jgo) on November 27, 2019; DOI <https://doi.org/10.1200/JGO.19.00025>

## INTRODUCTION

Hematologic malignancies (HMs) originate from uncontrolled growth of hematopoietic and lymphoid tissues. These biologically and clinically heterogeneous disorders account for 6.5% of all cancers around the world, including approximately 9.0% in the United States and Europe.<sup>1,2</sup> Less is known about HM epidemiology in Latin America (Central and South America). The region has witnessed a considerable increase in the amount of hematology and oncology research; however, most of the contributions

were observed in just a few countries (Brazil, Argentina, Mexico, Peru, Chile, and Uruguay).<sup>3</sup>

In the multinational CONCORD program, which estimates survival from cancer in 1.9 million adults from 101 population-based cancer registries in 31 countries on 5 continents, only 2 of the participating countries were located in Latin America.<sup>4</sup> Moreover, according to the WHO, only 8% of Latin American populations are covered by cancer registries.<sup>5</sup>

Real-world data on HMs in Latin America are needed to inform decisions about patient care and health

## CONTEXT

### Key Objective

Despite improved assessment and management of multiple myeloma, chronic lymphocytic leukemia (CLL), and non-Hodgkin lymphoma (NHL) around the world, there is a paucity of high-quality, real-world data on these diseases in Latin America. The aim of the HOLA study is to investigate patient and treatment characteristics to understand the unmet needs in cancer care in Latin America.

### Knowledge Generated

More than 5,000 patients were included from 7 Latin American countries, with the median age at diagnosis being slightly different from other regions' reports (range, 57 years in patients with NHL to 67 years in patients with CLL). Most patients had comorbid conditions, and there was considerable regional heterogeneity in characteristics related to both patients and their management.

### Relevance

Findings from this study can fill an important gap for physicians, patients, and health authorities in Latin America for the management of hematologic malignancies and can be used to understand the disease landscape in this region for further improvement of patient care.

policy. The past 15 years have brought paradigm shifts in diagnosis, staging, and treatment of HMs around the world, but progress in Latin America and the suitability (and potential effects) of new therapies for its residents are largely unknown.<sup>6-13</sup> The primary aim of the Hemato-Oncology Latin America (HOLA) study was to describe patient characteristics and treatment patterns in individuals with diagnoses of multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL) managed at oncology (tertiary care) hospitals in Latin American countries.

## METHODS

In this multicenter, observational study, the medical records of Latin American patients with CLL, MM, or NHL were retrospectively reviewed (ClinicalTrials.gov identifier: [NCT02559583](https://clinicaltrials.gov/ct2/show/study/NCT02559583)). Adults with HMs were studied at 30 oncology specialty hospitals in 7 countries: Argentina (4 private, 1 public setting), Brazil (1 private, 8 public settings), Chile (1 public setting), Colombia (5 private settings), Mexico (1 private, 5 public settings), Panama (1 private, 2 public settings), and Guatemala (1 public setting). The hospitals were selected based on their experience in providing clinical treatment to patients with CLL, MM, or NHL; geographical representation; the type of practice; interest in participating in the study; and fulfillment of the study requirements. All study sites were eligible to include all 3 types of cancer.

Patient population inclusion criteria were incident or prevalent CLL, MM, or NHL diagnosed between January 1, 2006, and December 31, 2015; age  $\geq 18$  years at the time of first observed diagnosis of these HMs (whether incident or prevalent);  $\geq 1$  year of patient data after first observed diagnosis (except in the event of patient death within 1 year of being diagnosed); and ability and willingness to provide informed consent (except if a waiver

of informed consent was obtained). There were no exclusion criteria.

The study was conducted under the Guidelines for Good Pharmacoepidemiology Practices issued by the International Society for Pharmacoepidemiology, the Declaration of Helsinki and its amendments, and any applicable national guidelines. Each study was approved by its local ethics committee and followed local country requirements (Brazil, approval by central ethics committee; Colombia, notification to Instituto Nacional de Vigilancia de Medicamentos y Alimentos; Argentina, approval by Direccion Nacional de Protección de Datos Personales; Mexico, approval by Secretaria de Salud/COFEPRIS, Comisión Nacional de Investigación Científicas; and Guatemala, notification to Ministerio de Salud Publica).

Each study site selected and prepared medical records for chart abstractors to review, and the principal investigator provided clarification in cases of doubt. The study employed chart abstractors with previous experience in performing medical record reviews, and the chart abstractors were centrally trained by Janssen Cilag personnel on the electronic data capture system, study protocol, and how to complete the electronic case report forms (CRFs). The data fields, such as laboratory results, diagnosis specification, and other clinical criteria in the CRFs, had predefined ranges in clickable fields as opposed to free-text fields. This was designed to ensure that the abstractor looked only for the required information in the medical chart and selected the field that contained the specific range in the CRF where the data fit. Each trained chart abstractor signed a training form to document training module completed and date of training. All training materials and records were available for review, and future chart abstractors were required to undergo the same training. Under source document verification visits

were performed at selected sites, which represented 60% of all study sites.

Demographic data, including sex, country of residence, age at diagnosis, and age category (< 30, 30 to < 40, 40 to < 50, 50 to < 60, 60 to < 70, 70 to < 80,  $\geq$  80 years) were collected. Clinical data included comorbidity status, disease stage, Eastern Cooperative Oncology Group (ECOG) performance status (PS), and first-contact physician type at diagnosis. Disease stage at diagnosis was based on International Staging System (ISS) for MM, Ann Arbor staging for NHL, and Binet/Rai stage for CLL. The subtype of NHL was also recorded. Treatment data included the time of treatment initiation and the treatment regimen of the induction therapy. Information about a patient's transplantation history was also collected from patients diagnosed with MM.

Descriptive statistical analyses were stratified by cancer type and country. Patient characteristics and treatment patterns were summarized using descriptive statistics,


including measures of central tendency (mean, median) and spread (variance, range, minimum, maximum) for continuous variables (eg, age at diagnosis) and frequency distributions (number, %) for categorical variables (eg, sex). Because of low overall enrollment, data from Panama and Guatemala were pooled for analysis. Treatment characteristics of patients with MM were further stratified by their history of transplantation (yes/no). Statistical analyses were conducted using SAS 9.2 software (SAS Institute, Cary, NC).

## RESULTS

Of a total of 5,140 patients, 2,967 (57.7%) had NHL, 1,518 (29.5%) had MM, and 655 (12.7%) had CLL. Among the original 5,140 patients, 2,715 (52.8%) were still being followed at the study end date (Fig 1).

### MM

Among 1,518 initially eligible individuals with MM, 713 (47.0%) were still being followed at the time of study end,



**FIG 1.** Disposition of (A) all patients and those with (B) multiple myeloma (MM), (C) chronic lymphocytic leukemia (CLL), and (D) non-Hodgkin lymphoma (NHL).

with a median follow-up of 2.2 years (range, < 0.1-12.1 years). One third of the patients with MM (506; 33.3%) died during the observation period (range, 18.4% in Panama/Guatemala to 54.4% in Brazil; Table 1). The median age at diagnosis was 61 years (range, 23-91 years). The most frequent age categories were 60 to < 70 years (31.1%) and 50 to < 60 years (28.3%). There was a slight predominance of males (50.7%) over females (49.3%), and the sex balance varied across regions (Table 2).

MM was highly comorbid with a range of chronic and other conditions, with approximately 53% of patients with one or two comorbidities and approximately 15% with more than two comorbidities. Hypertension was reported most frequently in 36.5% of patients (range, 28.2% in Argentina to

49.2% in Brazil). Other frequent comorbidities were diabetes and heart disease in 12.6% and 11.5% of patients, respectively. Potential manifestations of target organ damage included a history of bone disorders in 7.2% of patients and renal disease in 11.1% (Table 2).

At diagnosis, patients had an ECOG PS of 0 (27.2%), 1 (31.7%), or 2 (20.4%). Most patients were ISS stage II (29.4%) or III (48.8%). Stage III MM was the most frequently observed disease stage in Mexico (62.5%), Chile (60.0%), Brazil (49.3%), and Colombia (45.8%). Most Panamanian/Guatemalan patients (57.1%) had stage II, and most Argentinean patients had stage I (38.2%). Of patients with MM, 35% had renal impairment, which was fairly constant across countries. Of all patients with MM,

**TABLE 1.** Disposition of Patients With MM, CLL, and NHL

Characteristic	Country, No. (%)						
	Panama/ Guatemala (n = 178)	Chile (n = 571)	Argentina (n = 1,009)	Colombia (n = 918)	Mexico (n = 1,345)	Brazil (n = 1,119)	Total (N = 5,140)
<b>MM</b>							
Patients	49 (27.5)	99 (17.3)	284 (28.1)	338 (36.8)	364 (27.1)	384 (34.3)	1,518 (29.5)
Duration of follow-up,* years	44	94	260	327	350	367	1,442
Median	2.16	1.79	2.98	1.92	2.38	2.06	2.21
Minimum-maximum	0.1-9.7	0.1-11.7	< 0.1-12.1	< 0.1-9.4	< 0.1-10.2	< 0.1-9.7	< 0.1-12.1
Missing	5	5	24	11	14	17	76
Patients who died	9 (18.4)	41 (41.4)	70 (24.6)	103 (30.5)	74 (20.3)	209 (54.4)	506 (33.3)
Patients still being followed at end of study	28 (57.1)	23 (23.2)	173 (60.9)	128 (37.9)	204 (56.0)	157 (40.9)	713 (47.0)
<b>CLL</b>							
Patients	16 (9.0)	19 (3.3)	121 (12.0)	87 (9.5)	138 (10.3)	274 (24.5)	655 (12.7)
Duration of follow-up,* years	16	19	113	76	135	261	620
Median	1.64	3.43	2.99	2.45	3.83	3.01	3.03
Minimum-maximum	0.9-8.6	0.6-7.4	0.3-9.2	< 0.1-8.1	< 0.1-9.6	0.1-10.1	< 0.1-10.1
Missing	0	0	8	11	3	13	35
Patients who died	2 (12.5)	4 (21.1)	12 (9.9)	15 (17.2)	12 (8.7)	85 (31.0)	130 (19.8)
Patients still being followed at end of study	12 (75.0)	14 (73.7)	104 (86.0)	43 (49.4)	90 (65.2)	168 (61.3)	431 (65.8)
<b>NHL</b>							
Patients	113 (63.5)	453 (79.3)	604 (59.9)	493 (53.7)	843 (62.7)	461 (41.2)	2,967 (57.7)
Duration of follow-up,* years	104	442	577	471	796	431	2,821
Median	2.76	2.04	3.07	1.77	1.97	2.40	2.20
Minimum-maximum	< 0.1-9.9	< 0.1-8.8	< 0.1-11.8	< 0.1-8.4	< 0.1-10.1	< 0.1-9.7	< 0.1-11.8
Missing	9	11	27	22	47	30	146
Patients who died	6 (5.3)	60 (13.2)	120 (19.9)	130 (26.4)	176 (20.9)	199 (43.2)	691 (23.3)
Patients still being followed at end of study	90 (79.6)	173 (38.2)	440 (72.8)	191 (38.7)	451 (53.5)	226 (49.0)	1,571 (52.9)

Abbreviations: CLL, chronic lymphocytic leukemia; MM, multiple myeloma; NHL, non-Hodgkin lymphoma.

\*Follow-up defined as patients who were lost to follow-up or with ongoing follow-up from diagnosis to last consult date; for patients who died, from diagnosis to date of death.

**TABLE 2.** Demographics, Baseline Clinical Characteristics, and Treatment Patterns of Patients With Multiple Myeloma  
Country, No. (%)

Characteristic	Panama/ Guatemala (n = 49)	Chile (n = 99)	Argentina (n = 284)	Colombia (n = 338)	Mexico (n = 364)	Brazil (n = 384)	Total (n = 1,518)
Age at diagnosis, years	49	99	284	338	363	384	1,517
Mean (SD)	57.4 (13.0)	63.8 (11.0)	58.9 (11.1)	61.7 (11.9)	59.7 (11.2)	61.8 (10.8)	60.7 (11.4)
Median (range)	57 (29-85)	65 (27-85)	60 (25-91)	61 (23-91)	60 (28-88)	62 (27-90)	61 (23-91)
Unknown	0	0	0	0	1	0	1
Age category at diagnosis, years							
< 50	15 (30.6)	11 (11.1)	60 (21.1)	50 (14.8)	66 (18.2)	55 (14.3)	257 (16.9)
50 to < 60	14 (28.6)	24 (24.2)	81 (28.5)	101 (29.9)	112 (30.9)	97 (25.3)	429 (28.3)
60 to < 70	10 (20.4)	31 (31.3)	101 (35.6)	88 (26.0)	107 (29.5)	135 (35.2)	472 (31.1)
70 to < 80	7 (14.3)	30 (30.3)	29 (10.2)	78 (23.1)	68 (18.7)	78 (20.3)	290 (19.1)
≥ 80	3 (6.1)	3 (3.0)	13 (4.6)	21 (6.2)	10 (2.8)	19 (4.9)	69 (4.5)
Unknown	0	0	0	0	1	0	1
Sex							
Male	31 (63.3)	48 (48.5)	135 (47.5)	158 (46.7)	195 (53.6)	202 (52.6)	769 (50.7)
Female	18 (36.7)	51 (51.5)	149 (52.5)	180 (53.3)	169 (46.4)	182 (47.4)	749 (49.3)
No. of comorbidities at diagnosis							
0	17 (34.7)	14 (14.1)	102 (35.9)	82 (24.3)	177 (48.6)	4 (24.5)	486 (32.0)
1-2	28 (57.1)	61 (61.6)	146 (51.4)	194 (57.4)	155 (42.6)	225 (58.6)	809 (53.3)
> 2	4 (8.2)	24 (24.2)	36 (12.7)	62 (18.3)	32 (8.8)	65 (16.9)	223 (14.7)
Most frequent comorbidities at diagnosis							
Hypertension	17 (34.7)	41 (41.4)	80 (28.2)	113 (33.4)	114 (31.3)	189 (49.2)	554 (36.5)
Diabetes	7 (14.3)	20 (20.2)	15 (5.3)	31 (9.2)	58 (15.9)	61 (15.9)	192 (12.6)
Heart disease	5 (10.2)	14 (14.1)	45 (15.8)	40 (11.8)	28 (7.7)	43 (11.2)	175 (11.5)
Renal	5 (10.2)	22 (22.2)	18 (6.3)	39 (11.5)	13 (3.6)	71 (18.5)	168 (11.1)
Bone	4 (8.2)	3 (3.0)	24 (8.5)	52 (15.4)	6 (1.6)	20 (5.2)	109 (7.2)
ECOG PS at diagnosis							
0	5 (41.7)	20 (28.2)	7 (53.8)	15 (27.3)	9 (12.5)	16 (38.1)	72 (27.2)
1	1 (8.3)	28 (39.4)	3 (23.1)	24 (43.6)	16 (22.2)	12 (28.6)	84 (31.7)
2	3 (25.0)	10 (14.1)	0 (0.0)	11 (20.0)	24 (33.3)	6 (14.3)	54 (20.4)
3	3 (25.0)	10 (14.1)	2 (15.4)	2 (3.6)	16 (22.2)	7 (16.7)	40 (15.1)
≥ 4	0 (0.0)	3 (4.2)	1 (7.7)	3 (5.5)	7 (9.7)	1 (2.4)	15 (5.7)
Not available	37	28	271	283	292	342	1,253
ISS at diagnosis							
I	1 (7.1)	18 (25.7)	58 (38.2)	31 (18.7)	28 (14.0)	39 (19.4)	175 (21.8)
II	8 (57.1)	10 (14.3)	49 (32.2)	59 (35.5)	47 (23.5)	63 (31.3)	236 (29.4)
III	5 (35.7)	42 (60.0)	45 (29.6)	76 (45.8)	125 (62.5)	99 (49.3)	392 (48.8)
NE	2	0	2	1	0	1	6
Not available	33	29	130	171	164	182	709
Most frequent first-contact physician							
Hematologist	9 (18.8)	25 (25.3)	101 (35.6)	121 (35.8)	45 (12.4)	76 (19.8)	377 (24.9)
Internist	6 (12.5)	28 (28.3)	27 (9.5)	32 (9.5)	99 (27.2)	42 (10.9)	234 (15.4)
General physician	7 (14.6)	9 (9.1)	60 (21.1)	45 (13.3)	33 (9.1)	79 (20.6)	233 (15.4)
Patients who received a transplantation							
No. of patients who received chemotherapy	15	3	196	132	48	103	497
Time from initial diagnosis to treatment, days							
Mean (SD)	245.7 (806.70)	28.0 (26.87)	117.3 (310.72)	42.0 (91.17)	67.0 (243.56)	68.0 (142.40)	85.4 (262.80)
Median (range)	6.0 (0-2,806)	28.0 (9-47)	28.5 (0-2,584)	7.5 (0-467)	6.0 (0-1,201)	21.5 (0-849)	18.0 (0-2,806)
Missing	3	1	52	30	24	15	125

(Continued on following page)

**TABLE 2.** Demographics, Baseline Clinical Characteristics, and Treatment Patterns of Patients With Multiple Myeloma (Continued)

Characteristic	Country, No. (%)						
	Panama/ Guatemala (n = 49)	Chile (n = 99)	Argentina (n = 284)	Colombia (n = 338)	Mexico (n = 364)	Brazil (n = 384)	Total (n = 1,518)
Three most-used chemotherapy treatments							
Thalidomide based	1 (6.7)	1 (33.3)	91 (46.4)	12 (9.1)	15 (31.3)	31 (30.1)	151 (30.4)
Bortezomib based	11 (73.3)	0 (0.0)	40 (20.4)	18 (13.6)	6 (12.5)	5 (4.9)	125 (25.2)
CTD	0 (0.0)	1 (33.3)	12 (6.1)	3 (2.3)	6 (12.5)	31 (30.1)	53 (10.7)
Patients who did not receive a transplantation							
No. of patients who received chemotherapy	33	88	78	200	307	269	975
Time from initial diagnosis to treatment, days	19	66	65	154	243	233	780
Mean (SD)	72.1 (155.70)	109.2 (160.96)	56.6 (121.67)	28.7 (75.89)	34.6 (112.73)	62.5 (113.10)	50.8 (115.53)
Median (range)	16.0 (1.0-680.0)	58.0 (0-869.0)	23.0 (0-838.0)	4.0 (0-536.0)	9.0 (0-1461.0)	20.0 (0-784.0)	15.0 (0-1461.0)
Missing	14	22	13	46	64	36	195
Three most-used chemotherapy treatments							
Thalidomide based	3 (9.1)	26 (9.5)	22 (28.2)	29 (14.5)	152 (49.5)	76 (28.3)	308 (31.6)
Melphalan and thalidomide plus steroid	1 (3.0)	14 (15.9)	21 (26.9)	27 (13.5)	52 (16.9)	49 (18.2)	164 (16.8)
Melphalan plus steroid	1 (3.0)	18 (20.5)	6 (7.7)	10 (5.0)	17 (5.5)	36 (13.4)	88 (9.0)

Abbreviations: CTD, cyclophosphamide, thalidomide, and dexamethasone; ECOG PS, Eastern Cooperative Oncology Group performance status; ISS, International Staging System; NE, not estimated; SD, standard deviation.

first physician contact was with hematologists in 24.9% followed by 15.4% each with internists and general physicians.

In the entire cohort, 497 patients with MM (32.7%) underwent autologous hematopoietic stem-cell transplantation (ASCT); however, the proportion of patients who underwent transplantation varied among countries. The highest rate was 69.0% in Argentina, and the lowest was 3.0% in Chile. Median time from diagnosis to initial treatment was 18.0 days (range, 6.0 days in Panama/Guatemala and Mexico to 28.5 days in Argentina). The 497 transplantation recipients who received induction chemotherapy were treated predominantly with thalidomide-based (151; 30.4%) and bortezomib-based (125; 25.2%) regimens. In these patients, median time from diagnosis to initial treatment was 15.0 days (range, 4.0 days in Colombia to 58.0 days in Chile). Most patients with MM who did not undergo transplantation received thalidomide-based chemotherapy (308 of 975; 31.6%) or melphalan, thalidomide, and steroid treatment (164 of 975; 16.8%) at induction. Thalidomide-based chemotherapy was the preferred treatment in Argentina (28.2%), Mexico (49.5%), and Brazil (28.3%).

### CLL

Among 655 initially eligible individuals with CLL, 431 (65.8%) were still being followed at the time of study end, with a median follow-up of 3 years (< 0.1-10.1 years; Table 1). The proportion of patients with CLL who died during the observation period was 19.8% (range, 8.7% in Mexico to 31.0% in Brazil). Median age at diagnosis was 67 years (range, 23-96 years), which was relatively

consistent across countries (Table 2). The most frequent age categories were 60 to < 70 years (34.6%) and 70 to < 80 years (29.1%). There was a slight predominance of male (54.2%) over female (45.8%) patients with CLL.

A total of 468 (71.5%) of the 655 patients with CLL had comorbidities at diagnosis (Table 3). The most frequent comorbidity was hypertension observed in 46.1% (range, 37.5% in Panama/Guatemala to 73.7% in Chile); other common comorbidities were heart disease (15.7%) and diabetes (15.1%).

Approximately two thirds of patients with CLL presented with Binet stage A (66.5%) and/or Rai stage 0 or 1 (63.0%). Most patients (92.3%) had an ECOG PS of 0 or 1 (range, 81.3% in Chile to 93.6% in Brazil) at diagnosis. Compared with other specialties, the first physician contacted most frequently was with a hematologist (33.8%; range, 18.1% in Mexico to 84.2% in Chile). Other physicians were general physicians (23.6%) and internists (13.8%).

Of the 655 patients with CLL, 415 (63.4%) received chemotherapy. The most common initial treatment of CLL was chlorambucil with or without prednisone (191; 46.0%) followed by fludarabine, cyclophosphamide, and rituximab (FCR; 87; 21.0%) and fludarabine and cyclophosphamide (34; 8.2%). The majority of patients in Brazil (108 of 181; 59.7%) and Mexico (57 of 95; 60.0%) received chlorambucil with or without prednisone. FCR was the most frequent initial chemotherapy regimen in Argentina (53.6%), Panama/Guatemala (50.0%), Colombia (40%), and Chile (38.5%).

**TABLE 3.** Demographics, Baseline Clinical Characteristics, and Treatment Patterns of Patients With Chronic Lymphocytic Leukemia  
Country, No. (%)

Characteristic	Panama/ Guatemala (n = 16)	Chile (n = 19)	Argentina (n = 121)	Colombia (n = 87)	Mexico (n = 138)	Brazil (n = 274)	Total (n = 655)
Age at diagnosis, year	16	19	121	87	137	273	653
Mean (SD)	67.3 (10.4)	66.3 (9.2)	64.7 (10.4)	66.1 (12.7)	67.3 (10.0)	65.9 (11.0)	66.1 (10.9)
Median (range)	67 (47-82)	68 (46-88)	65 (39-95)	68 (33-91)	67 (38-93)	66 (23-96)	67 (23-96)
Unknown	0	0	0	0	1	1	2
Age category at diagnosis, years							
< 50	1 (6.3)	1 (5.3)	6 (5.0)	12 (13.8)	7 (5.1)	21 (7.7)	48 (7.4)
50 to < 60	2 (12.5)	3 (15.8)	31 (25.6)	14 (16.1)	25 (18.2)	49 (17.9)	124 (19.0)
60 to < 70	7 (43.8)	8 (42.1)	46 (38.0)	22 (25.3)	45 (32.8)	98 (35.9)	226 (34.6)
70 to < 80	4 (25.0)	6 (31.6)	28 (23.1)	25 (28.7)	47 (34.3)	80 (29.3)	190 (29.1)
≥ 80	2 (12.5)	1 (5.3)	10 (8.3)	14 (16.1)	13 (9.5)	25 (9.2)	65 (10.0)
Unknown	0	0	0	0	1	1	2
Sex							
Male	11 (68.8)	5 (26.3)	80 (66.1)	48 (55.2)	64 (46.4)	147 (53.6)	355 (54.2)
Female	5 (31.3)	14 (73.7)	41 (33.9)	39 (44.8)	74 (53.6)	127 (46.4)	300 (45.8)
No. of comorbidities at diagnosis							
0	5 (31.3)	1 (5.3)	36 (29.8)	23 (26.4)	46 (33.3)	76 (27.7)	187 (28.5)
1-2	8 (50.0)	11 (57.9)	56 (46.3)	52 (59.8)	77 (55.8)	161 (58.8)	365 (55.7)
> 2	3 (18.8)	7 (36.8)	29 (24.0)	12 (13.8)	15 (10.9)	37 (13.5)	103 (15.7)
Most frequent comorbidities at diagnosis							
Hypertension	6 (37.5)	14 (73.7)	52 (43.0)	38 (43.7)	56 (40.6)	136 (49.6)	302 (46.1)
Heart disease	1 (6.3)	1 (5.3)	49 (40.5)	9 (10.3)	15 (10.9)	28 (10.2)	103 (15.7)
Diabetes	3 (18.8)	7 (36.8)	12 (9.9)	9 (10.3)	31 (22.5)	37 (13.5)	99 (15.1)
ECOG PS at diagnosis							
0	0 (0.0)	11 (68.8)	10 (71.4)	3 (42.9)	15 (75.0)	34 (72.3)	73 (70.2)
1	0 (0.0)	2 (12.5)	3 (21.4)	3 (42.9)	5 (25.0)	10 (21.3)	23 (22.1)
2	0 (0.0)	2 (12.5)	0 (0.0)	0 (0.0)	0 (0.0)	2 (4.3)	4 (3.8)
3	0 (0.0)	1 (6.3)	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.1)	2 (1.9)
≥ 4	0 (0.0)	0 (0.0)	1 (7.1)	1 (14.3)	0 (0.0)	0 (0.0)	2 (1.9)
Not available	16	3	107	80	118	227	551
Binet staging at diagnosis							
A	3 (60.0)	6 (35.3)	39 (73.6)	49 (77.8)	56 (70.0)	115 (62.2)	268 (66.5)
B	0 (0.0)	6 (35.3)	8 (15.1)	3 (4.8)	9 (11.3)	32 (17.3)	58 (14.4)
C	2 (40.0)	5 (29.4)	6 (11.3)	11 (17.5)	15 (18.8)	38 (20.5)	77 (19.1)
NE	0	0	0	1	4	0	5
Not available	11	2	68	23	54	89	247
Rai staging at diagnosis							
0	4 (33.3)	5 (27.8)	23 (42.6)	12 (37.5)	40 (41.2)	54 (33.1)	138 (36.7)
1	5 (41.7)	3 (16.7)	15 (27.8)	8 (25.0)	24 (24.7)	44 (27.0)	99 (26.3)

(Continued on following page)

**TABLE 3.** Demographics, Baseline Clinical Characteristics, and Treatment Patterns of Patients With Chronic Lymphocytic Leukemia (Continued)

Characteristic	Country, No. (%)						
	Panama/ Guatemala (n = 16)	Chile (n = 19)	Argentina (n = 121)	Colombia (n = 87)	Mexico (n = 138)	Brazil (n = 274)	Total (n = 655)
2	0 (0.0)	6 (33.3)	6 (11.1)	3 (9.4)	10 (10.3)	27 (16.6)	52 (13.8)
3	1 (8.3)	1 (5.6)	8 (14.8)	5 (15.6)	11 (11.3)	18 (11.0)	44 (11.7)
4	2 (16.7)	3 (16.7)	2 (3.7)	4 (12.5)	12 (12.4)	20 (12.3)	43 (11.4)
NE	0	0	0	1	0	1	2
Not available	4	1	67	54	41	110	277
Most frequent first-contact physician							
Hematologist	3 (18.8)	16 (84.2)	69 (57.5)	41 (47.1)	25 (18.1)	67 (24.5)	221 (33.8)
General physician	8 (50.0)	2 (10.5)	42 (35.0)	10 (11.5)	29 (21.0)	63 (23.1)	154 (23.6)
Internist	2 (12.5)	1 (5.3)	4 (3.3)	16 (18.4)	55 (39.9)	12 (4.4)	90 (13.8)
Time from initial diagnosis to treatment, months							
Mean (SD)	12.8 (27.0)	14.0 (25.2)	19.2 (21.7)	5.5 (6.7)	9.4 (13.2)	10.0 (16.0)	11.2 (17.1)
Median (range)	2.0 (0.1-92.3)	3.3 (0.6-82.4)	11.3 (0.1-80.2)	2.1 (< 0.1-22.9)	2.3 (< 0.1-55.3)	3.2 (0-82.8)	3.5 (0-92.3)
Missing	0	0	7	11	12	19	49
Three most-used chemotherapy treatments							
Chlorambucil with or without prednisone	1 (8.3)	3 (23.1)	7 (10.1)	15 (33.3)	57 (60.0)	108 (59.7)	191 (46.0)
FCR	6 (50.0)	5 (38.5)	37 (53.6)	18 (40.0)	8 (8.4)	13 (7.2)	87 (21.0)
FC	0 (0.0)	1 (7.7)	5 (7.2)	1 (2.2)	4 (4.2)	23 (12.7)	34 (8.2)

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; FC, fludarabine and cyclophosphamide; FCR, fludarabine, cyclophosphamide, and rituximab; NE, not estimated; SD, standard deviation.

## NHL

Among 2,967 eligible individuals with NHL, 1,571 (52.9%) were still being followed at the time of study end, with a median follow-up of 2.2 years (< 0.1-11.8 years). The proportion of patients with NHL who died during the observation period was 23.3% (range, 5.3% in Panama/Guatemala to 43.2% in Brazil; [Table 1](#)). More than two thirds of patients with NHL (68.6%) had either diffuse large B-cell lymphoma (DLBCL; 1,457; 49.1%) or follicular lymphoma (FL; 578; 19.5%). This section focuses on these subpopulations. Additional descriptive data on individuals with mantle cell lymphoma and mucosa-associated lymphoid tissue (MALT) lymphoma are listed in [Appendix Tables A1](#) and [A2](#).

Median age at diagnosis was 58 years (range, 18-95 years) for DLBCL and 57 years (range, 18-92 years) for FL. These values showed considerable variation across countries. Sex was approximately evenly distributed in patients with DLBCL and slightly imbalanced toward females with FL ([Tables 4](#) and [5](#)).

Comorbidities were present in 59.1% of patients with DLBCL and 54.0% with FL. The most frequent comorbidity for patients with DLBCL was hypertension (29.0%) followed by diabetes (12.8%) and heart disease (8.0%). For patients with FL, the most frequent comorbidity was hypertension (27.7%) followed by diabetes (10.2%) and heart disease (6.6%).

At diagnosis, patients with DLBCL had an ECOG PS of 0 (46.9%) or 1 (32.0%). Approximately one third of patients with DLBCL (33.4%) who had available Ann Arbor disease staging data were classified as having stage IV; 24.4% had stage II disease, 24.3% had stage III, and 17.8% had stage I. A total of 29.4% of patients with FL had an ECOG PS, of whom 68.8% had a PS of 0 and 22.4% had a PS of 1. A total of 520 (90.0%) of 578 patients with FL had available staging data, with 33.1% having stage IV, 34.0% stage III, 19.6% stage II, and 13.3% stage I disease.

Among patients with DLBCL and FL, hematologists were most frequently the first physician contacted (28.9%)



**TABLE 4.** Demographics, Baseline Clinical Characteristics, and Treatment Patterns of Patients With Diffuse Large B-Cell Lymphoma  
Country, No. (%)

Characteristic	Panama/ Guatemala (n = 52)	Chile (n = 244)	Argentina (n = 252)	Colombia (n = 266)	Mexico (n = 442)	Brazil (n = 201)	Total (n = 1,457)
Age at diagnosis, years	51	244	252	266	442	200	1,455
Mean (SD)	53.3 (16.3)	58.7 (15.7)	57.4 (15.0)	56.0 (16.3)	56.9 (15.1)	55.7 (16.5)	56.8 (15.7)
Median (range)	57 (18-81)	61 (18-95)	60 (22-87)	58 (18-88)	56 (21-92)	57 (20-90)	58 (18-95)
Unknown	1	0	0	0	0	1	2
Age category at diagnosis, years							
< 50	19 (37.3)	63 (25.8)	71 (28.2)	89 (33.4)	146 (33.0)	69 (30.0)	448 (30.8)
50 to < 60	9 (17.6)	47 (19.3)	53 (21.0)	52 (19.5)	102 (23.1)	51 (25.5)	314 (21.6)
60 to < 70	16 (31.4)	73 (29.9)	73 (29.0)	67 (25.2)	93 (21.0)	51 (25.5)	373 (25.6)
70 to < 80	6 (11.8)	47 (19.3)	44 (17.5)	45 (16.9)	72 (16.3)	22 (11.0)	236 (16.2)
≥ 80	1 (2.0)	14 (5.7)	11 (4.4)	13 (4.9)	29 (6.6)	16 (8.0)	84 (5.8)
Unknown	1	0	0	0	0	1	2
Sex							
Male	27 (51.9)	126 (51.6)	134 (53.2)	137 (51.5)	210 (47.5)	86 (42.8)	720 (49.4)
Female	25 (48.1)	118 (48.4)	118 (46.8)	129 (48.5)	232 (52.5)	115 (57.2)	737 (50.6)
No. of comorbidities at diagnosis							
0	25 (48.1)	77 (31.6)	91 (36.1)	73 (27.4)	242 (54.8)	88 (43.8)	596 (40.9)
1-2	24 (46.2)	142 (58.2)	116 (46.0)	152 (57.1)	176 (39.8)	98 (48.8)	708 (48.6)
> 2	3 (5.8)	25 (10.2)	45 (17.9)	41 (15.4)	24 (5.4)	15 (7.5)	153 (10.5)
Most frequent comorbidities at diagnosis							
Hypertension	19 (36.5)	91 (37.3)	73 (29.0)	85 (32.0)	93 (21.0)	62 (30.8)	423 (29.0)
Diabetes	7 (13.5)	41 (16.8)	20 (7.9)	25 (9.4)	73 (16.5)	20 (10.0)	186 (12.8)
Heart disease	2 (3.8)	13 (5.3)	49 (19.4)	23 (8.6)	15 (3.4)	15 (7.5)	117 (8.0)
Other neoplasia	0 (0.0)	11 (4.5)	30 (11.9)	24 (9.0)	10 (2.3)	0 (0.0)	75 (5.1)
ECOG PS at diagnosis							
0	7 (100)	114 (55.9)	33 (45.2)	25 (34.2)	38 (33.0)	25 (56.8)	242 (46.9)
1	0 (0.0)	67 (32.8)	19 (26.0)	28 (38.4)	40 (34.8)	11 (25.0)	165 (32.0)
2	0 (0.0)	14 (6.9)	12 (16.4)	13 (17.8)	19 (16.5)	5 (11.4)	63 (12.2)
3	0 (0.0)	6 (2.9)	3 (4.1)	6 (8.2)	12 (10.4)	3 (6.8)	30 (5.8)
≥ 4	0 (0.0)	3 (1.5)	6 (8.2)	1 (1.4)	6 (5.2)	0 (0.0)	16 (3.1)
Not available	45	40	179	193	327	157	941
Ann Arbor stage							
I	6 (17.6)	47 (19.8)	36 (17.5)	33 (15.3)	77 (19.9)	17 (12.8)	216 (17.8)
II	10 (29.4)	68 (28.7)	47 (22.8)	56 (25.9)	86 (22.3)	29 (21.8)	296 (24.4)
III	8 (23.5)	56 (23.6)	61 (29.6)	49 (22.7)	91 (23.6)	30 (22.6)	295 (24.3)
IV	10 (29.4)	66 (27.8)	62 (30.1)	78 (36.1)	132 (34.2)	57 (42.9)	405 (33.4)
NE	7	0	40	24	26	0	97
Unknown	11	7	6	26	30	68	148

(Continued on following page)

**TABLE 4.** Demographics, Baseline Clinical Characteristics, and Treatment Patterns of Patients With Diffuse Large B-Cell Lymphoma (Continued)

Characteristic	Country, No. (%)						
	Panama/ Guatemala (n = 52)	Chile (n = 244)	Argentina (n = 252)	Colombia (n = 266)	Mexico (n = 442)	Brazil (n = 201)	Total (n = 1,457)
Most frequent first-contact physician							
Hematologist	6 (11.8)	181 (74.2)	84 (33.3)	75 (28.2)	56 (12.7)	19 (9.5)	421 (28.9)
General physician	12 (23.5)	19 (7.8)	64 (25.4)	92 (34.6)	62 (14.0)	55 (27.4)	304 (20.9)
Surgeon	8 (15.7)	12 (4.9)	38 (15.1)	18 (6.8)	106 (24.0)	9 (4.5)	191 (13.1)
Time from initial diagnosis to treatment, months							
Mean (SD)	1.1 (1.7)	1.9 (1.4)	1.2 (2.2)	0.8 (1.3)	0.9 (1.2)	1.8 (2.2)	1.2 (1.7)
Median (range)	0.7 (0-10.5)	1.6 (0-12.7)	0.7 (0-23.1)	0.3 (0-12.1)	0.5 (0-12.1)	1.0 (< 0.1-13.8)	0.8 (0-23.1)
Missing	8	27	19	60	83	25	222
Three most-used chemotherapy treatments							
R-CHOP	47 (92.2)	167 (70.2)	204 (81.6)	187 (72.2)	271 (63.3)	122 (62.9)	998 (70.3)
CHOP	2 (3.9)	65 (27.3)	10 (4.0)	13 (5.0)	72 (16.8)	46 (23.7)	208 (14.6)
RCVP	0 (0.0)	1 (0.4)	12 (4.8)	15 (5.8)	10 (2.3)	1 (0.5)	39 (2.7)

Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; ECOG PS, Eastern Cooperative Oncology Group performance status; NE, not estimated; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; RCVP, rituximab, cyclophosphamide, vincristine, and prednisone; SD, standard deviation.

followed by internists/general physicians (21.0%) and surgeons (13.7%). Only 8%-12% of patients in Brazil and Panama/Guatemala first consulted with a hematologist.

For patients with DLBCL, the 2 most frequent regimens were rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP; 70.3%) and cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; 14.6%). All other regimens were used by < 5% of patients. Similar trends were observed across countries. The majority of patients with FL received chemotherapy (546 of 578; 94.5%); the 3 most frequent regimens were R-CHOP (280 of 546; 51.3%), rituximab plus cyclophosphamide, vincristine, and prednisone (96 of 546; 17.6%), and CHOP (70 of 546; 12.8%). CHOP was the most frequently reported therapy in Chile (26 of 68; 38.2%) and Brazil (17 of 55; 30.9%).

## DISCUSSION

To our knowledge, the HOLA registry—unprecedented in size and scope—provides high-quality, real-world data from > 5,000 patients with HMs observed for 8 years in Latin America. Despite considerable heterogeneity across the 7 participating countries, certain common themes are of potential concern to health care providers and policy-makers. First, large proportions of patients with HMs had comorbidities, which can limit therapeutic options. Second, considerable numbers of patients also had high-grade and other aggressive forms of disease (eg, DLBCL), and approximately 26% of patients died during the observation period.

Our study identified potential regional access-to-care issues. Between 28% and 50% of patients with MM received thalidomide-based chemotherapy in Argentina, Brazil, Mexico, and Chile, and 36% of those in Colombia received bortezomib. Furthermore, there was wide variation between countries in the proportion of patients with MM who had undergone transplantation. In Argentina, 20-fold more patients underwent ASCT than in Chile. The treatment regimens in Latin American were different compared with those of other countries in the world. For example, the majority of transplantation recipients with MM were administered thalidomide-based (30.4%) or bortezomib-based (25.2%) treatment in the studied regions, while lenalidomide, bortezomib, and dexamethasone chemotherapy is the most commonly used frontline treatment of transplantation-eligible patients with MM in the United States. Differences in treatment regimens were probably due to the restricted access and lack of approved novel agents in these studied regions.

With regard to comorbidities, these included hypertension (range across HMs, 29.0%-46.1%), diabetes (12.6%-15.1%), and heart disease (8.0%-15.7%). In one study, patients with MM who received treatment with thalidomide experienced a 23% increase in grade 3-4 adverse events, including, most frequently, cardiovascular disease followed by other hematologic conditions, thromboembolic events, infection, and neuropathy.<sup>14</sup>

A Latin American observational study found the median age of patients with MM to be 67.4 years, and 70.7%

**TABLE 5.** Demographic, Baseline Clinical Characteristics, and Treatment Patterns of Patients With Follicular Lymphoma  
Country, No. (%)

Characteristic	Panama/ Guatemala (n = 21)	Chile (n = 75)	Argentina (n = 185)	Colombia (n = 62)	Mexico (n = 175)	Brazil (n = 60)	Total (n = 578)
Age at diagnosis, years	20	75	185	62	174	60	576
Mean (SD)	58.1 (12.0)	61.1 (13.7)	58.8 (11.8)	52.7 (12.8)	54.6 (12.4)	59.4 (13.6)	57.2 (12.8)
Median (range)	61 (34-81)	61 (18-84)	59 (26-90)	53 (29-82)	55 (21-92)	57 (37-92)	57 (18-92)
Unknown	1	0	0	0	1	0	2
Age category at diagnosis, years							
< 50	6 (30.0)	12 (16.1)	36 (19.4)	26 (41.9)	56 (32.2)	11 (18.4)	147 (25.5)
50 to < 60	2 (10.0)	21 (28.0)	64 (34.6)	18 (29.0)	58 (33.3)	25 (41.7)	188 (32.6)
60 to < 70	9 (45.0)	16 (21.3)	55 (29.7)	11 (17.7)	37 (21.3)	11 (18.3)	139 (24.1)
70 to < 80	2 (10.0)	22 (29.3)	19 (10.3)	6 (9.7)	20 (11.5)	7 (11.7)	76 (13.2)
≥ 80	1 (5.0)	4 (5.3)	11 (5.9)	1 (1.6)	3 (1.7)	6 (10.0)	26 (4.5)
Unknown	1	0	0	0	1	0	2
Sex							
Male	10 (47.6)	35 (46.7)	82 (44.3)	31 (50.0)	81 (46.3)	21 (35.0)	260 (45.0)
Female	11 (52.4)	40 (53.3)	103 (55.7)	31 (50.0)	94 (53.7)	39 (65.0)	318 (55.0)
No. of comorbidities at diagnosis							
0	7 (33.3)	26 (34.7)	69 (37.3)	31 (50.0)	106 (60.6)	27 (45.0)	266 (46.0)
1-2	12 (57.1)	40 (53.3)	95 (51.4)	26 (41.9)	65 (37.1)	26 (43.3)	264 (45.7)
> 2	2 (9.5)	9 (12.0)	21 (11.4)	5 (8.1)	4 (2.3)	7 (11.7)	48 (8.3)
Most frequent comorbidities at diagnosis							
Hypertension	13 (61.9)	30 (40.0)	55 (29.7)	10 (16.1)	30 (17.1)	22 (36.7)	160 (27.7)
Diabetes	1 (4.8)	9 (12.0)	13 (7.0)	4 (6.5)	26 (14.9)	6 (10.0)	59 (10.2)
Heart disease	1 (4.8)	3 (4.0)	28 (15.1)	2 (3.2)	3 (1.7)	1 (1.7)	38 (6.6)
ECOG PS at diagnosis							
0	4 (100)	50 (75.8)	32 (80.0)	8 (47.1)	17 (54.8)	6 (50.0)	117 (68.8)
1	0 (0.0)	12 (18.2)	7 (17.5)	6 (35.3)	9 (29.0)	4 (33.3)	38 (22.4)
2	0 (0.0)	3 (4.5)	1 (2.5)	2 (11.8)	5 (16.1)	2 (16.7)	13 (7.6)
3	0 (0.0)	0 (0.0)	0 (0.0)	1 (5.9)	0 (0.0)	0 (0.0)	1 (0.6)
≥ 4	0 (0.0)	1 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.6)
Not available	17	9	145	45	144	48	408
Ann Arbor stage at diagnosis							
I	6 (37.5)	9 (12.2)	29 (17.5)	5 (8.6)	16 (10.0)	4 (8.7)	69 (13.3)
II	6 (37.5)	15 (20.3)	32 (19.3)	11 (19.0)	28 (17.5)	10 (21.7)	102 (19.6)
III	3 (18.8)	24 (32.4)	51 (30.7)	26 (44.8)	59 (36.9)	14 (30.4)	177 (34.0)
IV	1 (6.3)	26 (35.1)	54 (32.5)	16 (27.6)	57 (35.6)	18 (39.1)	172 (33.1)
NE	0	0	17	1	3	0	21

(Continued on following page)

**TABLE 5.** Demographic, Baseline Clinical Characteristics, and Treatment Patterns of Patients With Follicular Lymphoma (Continued)

Characteristic	Country, No. (%)						
	Panama/ Guatemala (n = 21)	Chile (n = 75)	Argentina (n = 185)	Colombia (n = 62)	Mexico (n = 175)	Brazil (n = 60)	Total (n = 578)
Unknown	5	1	2	3	12	14	37
Missing, No.	0	0	0	0	0	0	0
Most frequent first-contact physician							
Hematologist	2 (9.5)	57 (76.0)	50 (27.0)	32 (51.6)	22 (12.6)	5 (8.3)	168 (29.1)
General physician	7 (33.3)	3 (4.0)	48 (25.9)	13 (21.0)	34 (19.4)	19 (31.7)	124 (21.5)
Surgeon	3 (14.3)	4 (5.3)	30 (16.2)	8 (12.9)	37 (21.1)	5 (8.3)	87 (15.1)
Time from initial diagnosis to treatment, months							
Mean (SD)	2.5 (3.44)	2.8 (3.99)	5.5 (12.25)	2.2 (4.30)	1.9 (5.74)	2.7 (4.04)	3.3 (8.25)
Median (range)	1.2 (0.1-13.4)	2.2 (< 0.1-30.6)	1.2 (< 0.1-74.7)	0.8 (< 0.1-20.8)	0.7 (0-60.3)	1.5 (< 0.1-21.8)	1.1 (0-74.7)
Missing	3	6	16	18	24	12	79
Three most-used chemotherapy treatments							
R-CHOP	12 (57.1)	19 (27.9)	101 (59.1)	35 (57.4)	97 (57.1)	16 (29.1)	280 (51.3)
RCVP	5 (23.8)	10 (14.7)	38 (22.2)	18 (29.5)	20 (11.8)	5 (9.1)	96 (17.6)
CHOP	2 (9.5)	26 (38.2)	3 (1.8)	0 (0.0)	22 (12.9)	17 (30.9)	70 (12.8)

Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; ECOG PS, Eastern Cooperative Oncology Group performance status; NE, not estimated; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; RCVP, rituximab, cyclophosphamide, vincristine, prednisone; SD, standard deviation.

studied were in ISS stage II or III. Approximately one third of patients received thalidomide as frontline therapy, and 26.9% received ASCT.<sup>15</sup> An analysis of medical records for 9,120 patients at a hematologic clinic in Puebla, Mexico, over 20 years identified 855 individuals with HMs, including 66 (7.7%) with MM; median age was 66 years, and 51% survived through 540 days. The authors contended that a range of immunoproliferative disorders are less frequent in the indigenous Mexican population (mestizos) compared with whites, including CLL (5 times less frequent) and monoclonal gammopathy of undetermined significance (4 times less frequent).<sup>16</sup>

In a series of 1,028 patients with NHL in Central America (Guatemala) and South America (Argentina, Brazil, Chile, and Peru), Laurini et al<sup>17</sup> had findings consistent with those of the HOLA study. Forty percent of patients with NHL had DLBCL. In the HOLA study, 49.1% of patients with NHL had DLBCL (63.5% in Panama/Guatemala). In all, 20.4% of Central and South American patients with NHL had FL; 6.9% had marginal zone B-cell lymphoma, MALT type; and 6.8% had peripheral T-cell lymphomas. Median age of Latin American patients with NHL was 59 years compared with 58 (in patients with DLBCL) in the HOLA

study. Other studies in Guatemala,<sup>17</sup> Mexico,<sup>18</sup> and Chile<sup>19</sup> echo the findings from the HOLA study, showing that DLBCL was the most frequent subtype of NHL and revealing that most patients had a B-cell rather than a T-cell lineage. The Guatemalan study of 226 consecutive biopsy samples showed that 44% of patients with NHL had DLBCL (median age, 58.5 years).<sup>17</sup>

The combination of the HOLA cohort size (N = 5,140) and broad scope of follow-up data (8 years) are study strengths. Given the liberal eligibility criteria and observational nature of the study, the findings should be generalizable to most Latin American practitioners' treatment populations and settings. Chart abstractors were centrally trained and had considerable expertise in using clearly prespecified disease definitions. On the other hand, the cohort represented a convenience population, which potentially reduces the generalizability of the findings. Because of potential medical surveillance bias, the prevailing tertiary care nature of the treatment milieu may have resulted in overestimations of the percentage of patients with HMs, comorbidities, and treatment patterns compared with less-specialized clinics. Given that Latin American cancer care delivery systems are largely skewed toward urban settings,

individuals who reside in rural locales may have been under-represented. Rural workers may experience greater vocational exposure to insecticides and other lymphomagens.<sup>20</sup> The International Classification of Diseases for Oncology codes used to identify patients with MM, CLL, and NHL were developed for reimbursement, not for case ascertainment purposes. Numbers of centers, and hence overall denominators in calculations, were somewhat small, especially in Chile and Panama/Guatemala.

## AFFILIATIONS

- <sup>1</sup>Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil
- <sup>2</sup>Faculdade de Ciências Médicas–Santa Casa de São Paulo, São Paulo, Brazil
- <sup>3</sup>FUNDALEU, Buenos Aires, Argentina
- <sup>4</sup>Fundacion Santa Fe de Bogotá, Bogotá, Colombia
- <sup>5</sup>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
- <sup>6</sup>ISSEMYM, Mexico City, Mexico
- <sup>7</sup>Hospital Sírio-Libanês, São Paulo, Brazil
- <sup>8</sup>Medical Solution SA, Guatemala City, Guatemala
- <sup>9</sup>Hospital Universitario Walter Cantidio, Fortaleza, Brazil
- <sup>10</sup>Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina
- <sup>11</sup>Instituto Nacional del Cancer, Santiago, Chile
- <sup>12</sup>Instituto de Oncología Ángel H. Roffo, Buenos Aires, Argentina
- <sup>13</sup>Hospital Italiano La Plata, Buenos Aires, Argentina
- <sup>14</sup>Hospital das Clinicas de Porto Alegre, Porto Alegre, Brazil
- <sup>15</sup>Hospital Pablo Tobón Uribe, Medellín, Colombia
- <sup>16</sup>Hospital Universitario “Dr José E. González,” Mexico City, Mexico
- <sup>17</sup>Hemato Oncólogos SA, Valle, Colombia
- <sup>18</sup>CEPHO, Santo André, Brazil
- <sup>19</sup>Hospital das Clinicas da Universidade Federal de Goiás, Goiânia, Brazil
- <sup>20</sup>Complejo Hospitalario Metropolitano Dr Annulfo Arias Madrid, Panama City, Panama
- <sup>21</sup>Fundacion Cardioinfantil, Bogotá, Colombia
- <sup>22</sup>Fundacao Faculdade Regional de Medicina São José do Rio Preto, São José do Rio Preto, Brazil
- <sup>23</sup>Hospital Angeles Lomas, Huixquilucan, Mexico
- <sup>24</sup>Complejo Médico de la PFA Churruca-Visca, Buenos Aires, Argentina
- <sup>25</sup>Hospital General de México, Mexico City, Mexico
- <sup>26</sup>Instituto de Ensino e Pesquisas São Lucas, São Paulo, Brazil
- <sup>27</sup>Hospital das Clinicas–Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
- <sup>28</sup>Fundacion Oftalmológica de Santander, Santander, Colombia
- <sup>29</sup>Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico
- <sup>30</sup>Janssen-Cilag Farmacêutica, São Paulo, Brazil
- <sup>31</sup>Janssen-Cilag Farmacêutica, Buenos Aires, Argentina

## CORRESPONDING AUTHOR

Paula Barreyro, MD, Janssen Pharmaceutical Companies of Johnson & Johnson, Janssen-Cilag Farmacêutica SA, Mendoza 1259, CP (1428), Buenos Aires, Argentina; e-mail: pbarreyr@its.jnj.com.

## EQUAL CONTRIBUTION

V.T.d.M.H., C.C., and M.P. contributed equally to this study and its report.

## SUPPORT

The HOLA registry and this article were supported financially by Janssen-Cilag Farmacêutica (São Paulo, Brazil).

In conclusion, the HOLA study generated an unprecedented level of high-quality, real-world evidence on the disease and treatment characteristics of patients with HMs. Considerable regional variations in HM management were observed, and the findings can likely be ascribed to heterogeneity in both patient characteristics and treatment patterns. Results from this study can be used to understand the disease landscape in Latin America. Future research is needed to explicitly associate observed trends with treatment outcomes.

## AUTHOR CONTRIBUTIONS

**Conception and design:** Vania Tietsche de Moraes Hungria, Carlos Chiattonne, Miguel Pavlovsky, Oscar Avendaño Flores, Ana L. Basquiera, Carmen Cao, Alicia Enrico, Kenny M. Galvez, Lineth Lopez, Deborah Martínez, Carolina Pavlovsky, Telma Santos, Odin de la Mora, Gerardo Machnicki, Mariana Fernandez, Paula Barreyro

**Administrative support:** Odin de la Mora

**Provision of study material or patients:** Miguel Pavlovsky, Gladys P. Agreda, Oscar Avendaño Flores, Ana L. Basquiera, Carmen Cao, Maria S. Cugliari, Alicia Enrico, Danielle Farias, Maria Jose Mela, Carlos E. Miguel, Roberto Ovilla, Luis Palmer, Carolina Pavlovsky, Christian Ramos, Claudia Lucia Sossa, Elena Tuna-Aguilar, Jorge Vela

**Collection and assembly of data:** Vania Tietsche de Moraes Hungria, Carlos Chiattonne, Miguel Pavlovsky, Lina M. Abenozo, Gladys P. Agreda, Jorge Armenta, Celso Arrais, Oscar Avendaño Flores, Fernando Barroso, Ana L. Basquiera, Carmen Cao, Maria S. Cugliari, Alicia Enrico, Laura M. Fogliatto, Kenny M. Galvez, David Gomez, Alvaro Diaz, Daniel de Iracema, Danielle Farias, Lineth Lopez, William Armando Mantilla, Deborah Martínez, Maria Jose Mela, Carlos E. Miguel, Luis Palmer, Carolina Pavlovsky, Christian Ramos, Guillermina Remaggi, Rodrigo Santucci, Sergio Schusterschitz, Claudia Lucia Sossa, Elena Tuna-Aguilar, Jorge Vela, Telma Santos, Odin de la Mora, Paula Barreyro

**Data analysis and interpretation:** Vania Tietsche de Moraes Hungria, Carlos Chiattonne, Miguel Pavlovsky, Gladys P. Agreda, Jorge Armenta, Oscar Avendaño Flores, Carmen Cao, Alicia Enrico, Laura M. Fogliatto, Kenny M. Galvez, Danielle Farias, Lineth Lopez, Deborah Martínez, Roberto Ovilla, Carolina Pavlovsky, Elena Tuna-Aguilar, Jorge Vela, Odin de la Mora, Gerardo Machnicki, Mariana Fernandez, Paula Barreyro

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to [www.asco.org/rwc](http://www.asco.org/rwc) or [ascopubs.org/jgo/site/misc/authors.html](http://ascopubs.org/jgo/site/misc/authors.html).

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](http://Open Payments)).

**Vania Tietsche de Moraes Hungria**

**Consulting or Advisory Role:** AbbVie, Amgen, Celgene, Janssen-Cilag, Takeda Pharmaceuticals

**Speakers' Bureau:** Amgen, Celgene, Janssen-Cilag, Takeda Pharmaceuticals, Bristol-Myers Squibb Brazil

**Carlos Chiattonne**

**Consulting or Advisory Role:** Roche, Takeda Pharmaceuticals, Janssen Pharmaceuticals

**Miguel Pavlovsky**

**Honoraria:** AbbVie, Pharmacyclics, Roche, Novartis, Janssen Pharmaceuticals

**Consulting or Advisory Role:** AbbVie, Pharmacyclics, Roche, Novartis, Janssen Pharmaceuticals

**Speakers' Bureau:** AbbVie, Pharmacyclics, Roche, Novartis, Janssen Pharmaceuticals

**Travel, Accommodations, Expenses:** Roche, Sanofi, AbbVie, Laboratorios Raffo

**Lina M. Abenzoza**

**Travel, Accommodations, Expenses:** AbbVie

**David Gomez**

**Consulting or Advisory Role:** Celgene, Janssen Pharmaceuticals, Takeda Pharmaceuticals

**Speakers' Bureau:** Bristol-Myers Squibb (Mexico), AbbVie, Novartis, Janssen Pharmaceuticals, Amgen

**Daniel de Iracema**

**Consulting or Advisory Role:** Daiichi Sankyo

**Travel, Accommodations, Expenses:** Roche, Bayer AG

**Danielle Farias**

**Consulting or Advisory Role:** Janssen Pharmaceuticals, Novartis, Amgen, Bristol-Myers Squibb, Roche, AbbVie, Libbs Farmacêutica, Celgene, Eurofarma

**Speakers' Bureau:** Janssen Pharmaceuticals, Novartis, Takeda Pharmaceuticals, Amgen, Roche, Libbs Farmacêutica, Bristol-Myers Squibb, Celgene

**Research Funding:** Novartis (Inst), Pfizer (Inst), GlaxoSmithKline (Inst), Janssen Pharmaceuticals (Inst), Takeda Pharmaceuticals (Inst), Celltrion (Inst), Boehringer Ingelheim (Inst), Libbs Farmacêutica (Inst), AbbVie (Inst), Daiichi Sankyo (Inst), Bristol-Myers Squibb (Inst), Sanofi (Inst), AstraZeneca (Inst), Viracta Therapeutics (Inst)

**Travel, Accommodations, Expenses:** Roche, AbbVie, Takeda Pharmaceuticals, Amgen, Janssen Pharmaceuticals

**William Armando Mantilla**

**Employment:** Pfizer (I)

**Leadership:** Hemato-Oncologos Asociados

**Stock and Other Ownership Interests:** Pfizer (I)

**Honoraria:** Amgen, Pfizer, Roche, Janssen-Cilag

**Consulting or Advisory Role:** Bristol-Myers Squibb, Pfizer, Roche, Amgen

**Research Funding:** Pfizer (Inst)

**Travel, Accommodations, Expenses:** Roche, Janssen-Cilag, Novartis, Abbott Laboratories, Takeda Pharmaceuticals

**Deborah Martínez**

**Consulting or Advisory Role:** Celgene

**Research Funding:** Takeda Pharmaceuticals

**Travel, Accommodations, Expenses:** Celgene

**Carlos E. Miguel**

**Speakers' Bureau:** Janssen-Cilag

**Travel, Accommodations, Expenses:** Janssen-Cilag

**Guillermina Remaggi**

**Consulting or Advisory Role:** Amgen, Janssen-Cilag

**Speakers' Bureau:** Janssen Pharmaceuticals

**Rodrigo Santucci**

**Consulting or Advisory Role:** AbbVie, AstraZeneca

**Speakers' Bureau:** Janssen-Cilag

**Sergio Schusterschitz**

**Travel, Accommodations, Expenses:** Roche

**Claudia Lucia Sossa**

**Speakers' Bureau:** Novartis, Takeda Pharmaceuticals, Novo Nordisk, Abbott Laboratories

**Research Funding:** Baxter, Bayer AG, Roche

**Telma Santos**

**Employment:** Janssen Oncology

**Leadership:** Janssen-Cilag

**Stock and Other Ownership Interests:** Janssen-Cilag

**Odin de la Mora**

**Employment:** Janssen Oncology, Roche, Genentech, Novo Nordisk, Novartis

**Honoraria:** Takeda Pharmaceuticals

**Gerardo Machnicki**

**Employment:** Janssen Pharmaceuticals

**Stock and Other Ownership Interests:** Janssen Pharmaceuticals

**Mariana Fernandez**

**Employment:** Janssen-Cilag

**Paula Barreyro**

**Employment:** Janssen-Cilag

**Stock and Other Ownership Interests:** Janssen-Cilag

No other potential conflicts of interest were reported.

**ACKNOWLEDGMENT**

We thank Stephen W. Gutkin (WG Advanced Health Analytics) for assistance (with support from the study sponsor) in manuscript preparation according to Strengthening the Reporting of Observational Studies in Epidemiology guidelines. We also thank Yan Wang, PhD (WG Advanced Health Analytics) for reviewing the manuscript and making substantive intellectual contributions to its content.

**REFERENCES**

1. Dighiero G, Hamblin TJ: Chronic lymphocytic leukaemia. *Lancet* 371:1017-1029, 2008
2. Hossain MS, Iqbal MS, Khan MA, et al: Diagnosed hematological malignancies in Bangladesh - a retrospective analysis of over 5000 cases from 10 specialized hospitals. *BMC Cancer* 14:438, 2014
3. Acevedo AM, Gómez A, Becerra HA, et al: Distribution and trends of hematology and oncology research in Latin America: A decade of uncertainty. *Cancer* 120:1237-1245, 2014
4. Curado MP, de Souza DL: Cancer burden in Latin America and the Caribbean. *Ann Glob Heal* 80:370-377, 2014
5. International Agency for Research on Cancer: CI5: Cancer Incidence in Five Continents. Lyon, France, IARC, 2014
6. Burger JA, Tedeschi A, Barr PM, et al: Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. *N Engl J Med* 373:2425-2437, 2015
7. Hungria VTM, Maiolino A, Martinez G, et al: Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma. *Haematologica* 93:791-792, 2008
8. Eichhorst B, Robak T, Ghia P, et al: Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 26:v78-v84, 2015
9. Ludwig H, Sonneveld P, Davies F, et al: European perspective on multiple myeloma treatment strategies in 2014. *Oncologist* 19:829-844, 2014

10. Rajkumar SV, Dimopoulos MA, Palumbo A, et al: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol* 15:e538-e548, 2014
  11. Palumbo A, Rajkumar SV, San Miguel JF, et al: International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. *J Clin Oncol* 32:587-600, 2014
  12. Hallek M, Cheson BD, Catovsky D, et al: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. *Blood* 111:5446-5456, 2008
  13. Brenner H, Gondos A, Pulte D: Recent major improvement in long-term survival of younger patients with multiple myeloma. *Blood* 111:2521-2526, 2008
  14. Hungria VTDM, Crusoe EQ, Quero AA, et al: Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012. *Rev Bras Hematol Hemoter* 35:201-217, 2013
  15. Hungria VTM, Maiolino A, Martinez G, et al: Observational study of multiple myeloma in Latin America. *Ann Hematol* 96:65-72, 2017
  16. Ruiz-Argüelles GJ, Gómez-Rangel JD, Ruiz-Delgado GJ, et al: Multiple myeloma in Mexico: A 20-year experience at a single institution. *Arch Med Res* 35:163-167, 2004
  17. Laurini JA, Perry AM, Boilesen E, et al: Classification of non-Hodgkin lymphoma in Central and South America: A review of 1028 cases. *Blood* 120:4795-4801, 2012
  18. Perry AM, Molina-Kirsch H, Nathwani BN, et al: Classification of non-Hodgkin lymphomas in Guatemala according to the World Health Organization system. *Leuk Lymphoma* 52:1681-1688, 2011
  19. Alavanja MC, Hofmann JN, Lynch CF, et al: Non-Hodgkin lymphoma risk and insecticide, fungicide and fumigant use in the Agricultural Health Study. *PLoS One* 9:e109332, 2014
  20. Vlaanderen J, Lan Q, Kromhout H, et al: Occupational benzene exposure and the risk of lymphoma subtypes: A meta-analysis of cohort studies incorporating three study quality dimensions. *Environ Health Perspect* 119:159-167, 2011
- 



## APPENDIX

TABLE A1. Baseline Characteristics of Patients With Mantle Cell Lymphoma

Characteristic	Country, No. (%)						
	Panama/ Guatemala (n = 9)	Chile (n = 20)	Argentina (n = 37)	Colombia (n = 38)	Mexico (n = 38)	Brazil (n = 41)	Total (n = 183)
Age at diagnosis, years	9	20	37	38	38	41	183
Mean (SD)	60.8 (16.3)	60.4 (11.5)	59.4 (12.4)	62.9 (10.7)	61.6 (15.2)	63.2 (11.4)	61.6 (12.5)
Median (range)	61 (38-93)	58 (39-85)	60 (39-82)	63 (36-88)	63 (27-84)	63 (39-87)	61 (27-93)
Unknown							
Age category at diagnosis, years							
< 50	2 (22.2)	2 (10.0)	11 (29.7)	4 (10.5)	7 (18.5)	6 (14.6)	32 (17.5)
50 to < 60	2 (22.2)	9 (45.0)	7 (18.9)	9 (23.7)	7 (18.4)	11 (26.8)	45 (24.6)
60 to < 70	3 (33.3)	5 (25.0)	11 (29.7)	15 (39.5)	11 (28.9)	12 (29.3)	57 (31.1)
70 to < 80	1 (11.1)	3 (15.0)	4 (10.8)	9 (23.7)	9 (23.7)	9 (22.0)	35 (19.1)
≥ 80	1 (11.1)	1 (5.0)	4 (10.8)	1 (2.6)	4 (10.5)	3 (7.3)	14 (7.7)
Unknown							
Sex							
Male	7 (77.8)	12 (60.0)	30 (81.1)	27 (71.1)	26 (68.4)	26 (63.4)	128 (69.9)
Female	2 (22.2)	8 (40.0)	7 (18.9)	11 (28.9)	12 (31.6)	15 (36.6)	55 (30.1)
No. of comorbidities at diagnosis							
0	1 (11.1)	6 (30.0)	15 (40.5)	17 (44.7)	21 (55.3)	14 (34.1)	74 (40.4)
1-2	7 (77.8)	10 (50.0)	16 (43.2)	18 (47.4)	12 (31.6)	24 (58.5)	87 (47.5)
> 2	1 (11.1)	4 (20.0)	6 (16.2)	3 (7.9)	5 (13.2)	3 (7.3)	22 (12.0)
Most frequent comorbidities at diagnosis							
Hypertension	5 (55.6)	8 (40.0)	12 (32.4)	8 (21.1)	9 (23.7)	15 (36.6)	57 (31.1)
Diabetes	3 (33.3)	6 (30.0)	4 (10.8)	4 (10.5)	5 (13.2)	3 (7.3)	25 (13.7)
Heart disease	2 (22.2)	1 (5.0)	9 (24.3)	4 (10.5)	4 (10.5)	2 (4.9)	22 (12.0)
ECOG PS at diagnosis							
0	0 (0.0)	12 (66.7)	9 (81.8)	4 (66.7)	5 (41.7)	3 (75.0)	33 (63.5)
1	0 (0.0)	5 (27.8)	0 (0.0)	0 (0.0)	6 (50.0)	0 (0.0)	11 (21.2)
2	1 (100)	1 (5.6)	2 (18.2)	2 (33.3)	1 (8.3)	1 (25.0)	8 (15.4)
3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Not available	8	2	26	32	26	37	131
Ann Arbor stage at diagnosis							
I	1 (50.0)	4 (21.1)	1 (3.6)	2 (6.1)	2 (6.1)	2 (5.4)	12 (7.9)
II	0 (0.0)	3 (15.8)	1 (3.6)	2 (6.1)	2 (6.1)	2 (5.4)	10 (6.6)
III	0 (0.0)	5 (26.3)	4 (14.3)	5 (15.2)	7 (21.2)	2 (5.4)	23 (5.1)

(Continued on following page)



**TABLE A1.** Baseline Characteristics of Patients With Mantle Cell Lymphoma (Continued)

Characteristic	Country, No. (%)						
	Panama/ Guatemala (n = 9)	Chile (n = 20)	Argentina (n = 37)	Colombia (n = 38)	Mexico (n = 38)	Brazil (n = 41)	Total (n = 183)
IV	1 (50.0)	7 (36.8)	22 (78.6)	24 (72.7)	22 (66.7)	31 (83.8)	107 (70.4)
NE	3	0	9	3	1	0	16
Unknown	4	1	0	2	4	4	15
Most frequent first-contact physician							
Hematologist	3 (33.3)	15 (75.0)	13 (35.1)	16 (42.1)	6 (15.8)	4 (9.8)	57 (31.1)
General physician	1 (11.1)	3 (15.0)	12 (32.4)	11 (28.9)	4 (10.5)	6 (14.6)	37 (20.2)
Surgeon	2 (22.2)	2 (10.0)	7 (18.9)	3 (7.9)	5 (13.2)	1 (2.4)	20 (10.9)
Time from initial diagnosis to treatment, months							
Mean (SD)	0.4 (0.4)	1.5 (0.7)	4.6 (12.5)	0.7 (1.3)	1.3 (1.4)	2.3 (1.8)	2.1 (5.9)
Median (range)	0.3 (< 0.1-0.2)	1.6 (< 0.1-2.9)	1.1 (< 0.1-63.3)	0.2 (0-6.0)	0.7 (< 0.1-4.2)	1.6 (< 0.1-6.3)	0.9 (0-63.3)
Missing	3	5	4	10	13	7	42
Three most-used chemotherapy treatments							
R-CHOP	3 (33.3)	5 (26.3)	13 (41.9)	20 (54.1)	15 (41.7)	15 (37.5)	71 (41.3)
CHOP	2 (22.2)	11 (57.9)	0 (0.0)	3 (8.1)	0 (0.0)	12 (30.0)	28 (16.3)
Hyper CVAD	1 (11.1)	2 (10.5)	1 (3.2)	1 (2.7)	8 (22.2)	5 (12.5)	18 (10.5)

Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; ECOG PS, Eastern Cooperative Oncology Group performance status; NE, not estimated; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; SD, standard deviation.

**TABLE A2.** Baseline Characteristics of Patients With Mucosa-Associated Lymphoid Tissue Lymphoma

Characteristic	Country, No. (%)						
	Panama/ Guatemala (n = 4)	Chile (n = 14)	Argentina (n = 17)	Colombia (n = 12)	Mexico (n = 23)	Brazil (n = 14)	Total (n = 84)
Age at diagnosis, years	4	14	17	12	23	14	84
Mean (SD)	67.8 (8.7)	64.2 (17.2)	56.4 (17.2)	57.8 (13.1)	49.4 (17.9)	61.6 (14.5)	57.4 (16.8)
Median (range)	65 (61-80)	67 (21-86)	55 (29-88)	63 (31-74)	47 (18-82)	63 (35-77)	62 (18-88)
Age category at diagnosis, years							
< 50	0	2 (14.2)	7 (41.2)	3 (25.0)	13 (56.5)	3 (21.4)	28 (33.3)
50 to < 60	0	2 (14.3)	3 (17.6)	2 (16.7)	3 (13.0)	2 (14.3)	12 (14.3)
60 to < 70	3 (75.0)	3 (21.4)	1 (5.9)	5 (41.7)	4 (17.4)	3 (21.4)	19 (22.6)
70 to < 80	0	5 (35.7)	5 (29.4)	2 (16.7)	2 (8.7)	6 (42.9)	20 (23.8)
≥ 80	1 (25.0)	2 (14.3)	1 (5.9)	0	1 (4.3)	0	5 (6.0)
Sex							
Male	1 (25.0)	8 (57.1)	10 (58.8)	4 (33.3)	6 (26.1)	7 (50.0)	36 (42.9)
Female	3 (75.0)	6 (42.9)	7 (41.2)	8 (66.7)	17 (73.9)	7 (50.0)	48 (57.1)
No. of comorbidities at diagnosis							
0	0 (0.0)	4 (28.6)	5 (29.4)	1 (8.3)	18 (78.3)	1 (7.1)	29 (34.5)
1-2	4 (100)	9 (64.3)	10 (58.8)	11 (91.7)	5 (21.7)	12 (85.7)	51 (60.7)
> 2	0 (0.0)	1 (7.1)	2 (11.8)	0 (0.0)	0 (0.0)	1 (7.1)	4 (4.8)
Most frequent comorbidities at diagnosis							
Hypertension	4 (100)	7 (50.0)	4 (23.5)	2 (16.7)	4 (17.4)	7 (50.0)	28 (33.3)
Diabetes	1 (25.0)	4 (28.6)	1 (5.9)	1 (8.3)	1 (4.3)	5 (35.7)	13 (15.5)
Heart disease	1 (25.0)	0 (0.0)	3 (17.6)	1 (8.3)	0 (0.0)	1 (7.1)	6 (7.1)
Infections	1 (25.0)	0 (0.0)	2 (11.8)	2 (16.7)	1 (4.3)	0 (0.0)	6 (7.1)
ECOG PS at diagnosis							
0	0 (0.0)	6 (60.0)	5 (71.4)	0 (0.0)	4 (66.7)	1 (100)	16 (64.0)
1	0 (0.0)	4 (40.0)	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	5 (20.0)
2	0 (0.0)	0 (0.0)	2 (28.6)	1 (100)	0 (0.0)	0 (0.0)	3 (12.0)
3	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	0 (0.0)	1 (4.0)
≥ 4	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Not available	4	4	10	11	17	13	59
Ann Arbor stage at diagnosis							
I	0 (0.0)	6 (42.9)	2 (22.2)	1 (25.0)	9 (52.9)	0 (0.0)	18 (36.0)
II	0 (0.0)	4 (28.6)	3 (33.3)	1 (25.0)	4 (23.5)	1 (16.7)	13 (26.0)
III	0 (0.0)	3 (21.4)	3 (33.3)	0 (0.0)	1 (5.9)	0 (0.0)	7 (14.0)
IV	0 (0.0)	1 (7.1)	1 (11.1)	2 (50.0)	3 (17.6)	5 (83.3)	12 (24.0)
NE	3	0	8	3	1	0	15
Unknown	1	0	0	5	5	8	19

(Continued on following page)

**TABLE A2.** Baseline Characteristics of Patients With Mucosa-Associated Lymphoid Tissue Lymphoma (Continued)

Characteristic	Country, No. (%)						
	Panama/ Guatemala (n = 4)	Chile (n = 14)	Argentina (n = 17)	Colombia (n = 12)	Mexico (n = 23)	Brazil (n = 14)	Total (n = 84)
Most frequent first-contact physician							
Hematologist	0 (0.0)	10 (71.4)	7 (41.2)	6 (50.0)	2 (8.7)	0 (0.0)	25 (29.8)
General physician	3 (75.0)	0 (0.0)	1 (5.9)	2 (16.7)	5 (21.7)	3 (21.4)	14 (16.7)
Surgeon	0 (0.0)	2 (14.3)	8 (47.1)	1 (8.3)	1 (4.3)	0 (0.0)	12 (14.3)
Time from initial diagnosis to treatment, months							
Mean (SD)	2.1 (1.20)	3.8 (2.11)	9.8 (13.79)	1.4 (1.44)	2.1 (1.89)	9.3 (12.92)	4.8 (8.29)
Median (range)	2.2 (0.9-3.3)	3.4 (1.1-7.8)	2.2 (< 0.1-41.9)	0.9 (< 0.1-4.8)	1.1 (< 0.1-6.2)	3.9 (0.5-42.1)	2.3 (< 0.1-42.1)
Missing	1	2	2	0	4	1	10
Three most-used chemotherapy treatments							
R-CHOP	1 (25.0)	1 (8.3)	6 (50.0)	3 (30.0)	11 (57.9)	2 (20.0)	24 (35.8)
CHOP	0 (0.0)	8 (66.7)	0 (0.0)	0 (0.0)	3 (15.8)	1 (10.0)	12 (17.9)
RCVP	3 (75.0)	0 (0.0)	1 (8.3)	3 (30.0)	1 (5.3)	1 (10.0)	9 (13.4)

Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; ECOG PS, Eastern Cooperative Oncology Group performance status; NE, not estimated; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; RCVP, rituximab, cyclophosphamide, vincristine, and prednisone; SD, standard deviation.